Judges: Elaine D. Kaplan
Filed: Aug. 12, 2019
Latest Update: Mar. 03, 2020
Summary: In the Anited States Court of Federal Clarns (Pro Se) No. 15-095V (Filed Under Seal: July 22, 2019 | Reissued: August 12, 2019)" ) Keywords: Motion for Review; Vaccine GLORIA MASSEY CHINEA, ) Act; Expert Testimony; Onset; Causation; ) Guillain-Barré Syndrome (GBS) Petitioner, Vv. SECRETARY OF HEALTH AND HUMAN SERVICES, Respondent. Smee” Sinemet” See” nme” ingen” met” age” ine” ee” Gloria Massey Chinea, Oxnard, CA, pro se. Christine M. Becer, Trial Attorney, Torts Branch, Civil Division, U.S. Dep
Summary: In the Anited States Court of Federal Clarns (Pro Se) No. 15-095V (Filed Under Seal: July 22, 2019 | Reissued: August 12, 2019)" ) Keywords: Motion for Review; Vaccine GLORIA MASSEY CHINEA, ) Act; Expert Testimony; Onset; Causation; ) Guillain-Barré Syndrome (GBS) Petitioner, Vv. SECRETARY OF HEALTH AND HUMAN SERVICES, Respondent. Smee” Sinemet” See” nme” ingen” met” age” ine” ee” Gloria Massey Chinea, Oxnard, CA, pro se. Christine M. Becer, Trial Attorney, Torts Branch, Civil Division, U.S. Depa..
More
In the Anited States Court of Federal Clarns
(Pro Se)
No. 15-095V
(Filed Under Seal: July 22, 2019 | Reissued: August 12, 2019)"
) Keywords: Motion for Review; Vaccine
GLORIA MASSEY CHINEA, ) Act; Expert Testimony; Onset; Causation;
) Guillain-Barré Syndrome (GBS)
Petitioner,
Vv.
SECRETARY OF HEALTH AND HUMAN
SERVICES,
Respondent.
Smee” Sinemet” See” nme” ingen” met” age” ine” ee”
Gloria Massey Chinea, Oxnard, CA, pro se.
Christine M. Becer, Trial Attorney, Torts Branch, Civil Division, U.S. Department of Justice,
Washington, DC, with whom were C. Salvatore D’Alessio, Acting Director, Catharine E.
Reeves, Deputy Director, Alexis B. Babcock, Assistant Director, and Joseph H. Hunt, Assistant
Attorney General, for Respondent.
OPINION AND ORDER
KAPLAN, Judge.
Petitioner Gloria Massey Chinea seeks review of a decision of Special Master Brian
Corcoran rejecting her claim for compensation under the National Vaccine Injury Compensation
Program, 42 U.S.C. §§ 300aa-10 et seq. (“the Vaccine Act”). Ms. Chinea challenges the Special
Master’s conclusion that she failed to establish that the flu vaccine she received caused her
Guillain-Barré syndrome (“GBS”).
For the reasons set forth below, the Court concludes that the Special Master’s decision is
not arbitrary, capricious, or contrary to law. Ms. Chinea’s motion for review must therefore be
DENIED.
" This opinion was previously issued under seal on July 22, 2019. The parties were given the
opportunity to propose redactions on or before August 5, 2019. Because the parties have not filed
proposed redactions, the Court reissues its decision in its entirety.
BACKGROUND
The Special Master’s decision in this case contains a comprehensive and thorough
discussion of all of the evidence of record. What follows is a summary of those aspects of the
record most pertinent to the issues raised in Ms. Chinea’s petition for review.
L The Evidence Regarding Ms. Chinea’s Health Between Her Flu Vaccination and the
Diagnosis of GBS Three Months Later
On October 31, 2012, Ms. Chinea (then fifty-six years old) underwent a routine physical
with her primary care physician, Dr. Sergio Neira. Pet’r’s Ex. 1, at 1, 43, Docket No. 7 (Dr.
Neira’s Health Screening Report). Dr. Neira’s notes reflect that Ms. Chinea was experiencing
allergy-related wheezing, and he recorded her then-current conditions of conductive hearing loss,
fatigue, and post-herpetic neuralgia.
Id. at 11-12. Ms. Chinea received a flu vaccination in her
left deltoid during the same visit.
Id. at 1, 43.
At the time of the vaccination, Ms. Chinea served as Director of Activities for Alma Joy
Villa, a residential facility for the elderly that she opened in 2009. Hr’g Tr. at 7, 17, Docket No.
83. Ms. Chinea has described herself as a “healthy and vibrant individual with abundant energy”
before the vaccination, and characterized her life as a busy and active one. Pet’r’s Decl. at 2,
Docket No. 2; Hr’g Tr. 6-7; see also Hr’g Tr. 127-29 (testimony of Mr. Chinea, Ms. Chinea’s
husband, describing her usual high energy level); Hr’g Tr. 186-87 (testimony of a friend
describing Ms. Chinea as “a dynamo”).
Ms, Chinea testified that a week or two after she received her flu vaccination she began
experiencing a lack of energy. Hr’g Tr. at 19, 52, 80. She recalled missing a meeting in mid-
November because she overslept.
Id. at 23. She testified that on Thanksgiving, she “didn’t have
much energy” and was unable to participate in her usual holiday activities.
Id. at 26. A friend
testified that during a Thanksgiving celebration they both attended, Ms. Chinea was quiet, tired,
and walking slowly.
Id. at 170~71, 175; see also
id. at 192-93 (another friend describing Ms.
Chinea as “exhausted” and “quiet” during Thanksgiving holiday). Ms. Chinea recalled that in
addition to a lack of energy during this time period, she was experiencing a heightened
sensitivity to touch, the sensation of an “overgrown” tongue, and a metallic taste in her mouth, as
well as intermittent tingling in her hands and toes, among other symptoms.
Id. at 23-31.
The record also contains testimony concerning Ms. Chinea’s state of health in December
2012. According to her declaration, Ms. Chinea was unabie to participate in annual church
celebrations that month because she “was not feeling well.” Pet’r’s Decl. at 3. She also recalled
experiencing extreme fatigue that limited her involvement at a family Christmas gathering. Id.;
see also Hr’g Tr. 111-13 (testimony of friend regarding Ms. Chinea’s lack of energy during two
social engagements in December), One family friend testified that at a dinner at Outback
Steakhouse in December 2012, Ms. Chinea “started gasping for breath and choking” on a piece
of meat. Hr’g Tr. at 46-47, 196-97,
Ms. Chinea submitted five declarations from family members and friends, attesting to the
fact that she had decreased energy during the early weeks of November, and that the fatigue
continued into December. See generally Pet’r’s Ex. 61-65, Docket No. 62. The declarants also
referenced other symptoms they observed Ms. Chinea suffering from during this time period,
including voice problems, arm pain, low stamina, shortness of breath, and loss of appetite.
Pet’r’s Ex. 61, at 4 (Hovarth Declaration); Pet’r’s Ex. 62, at 4 (Neilson Declaration); Pet’r’s Ex.
63, at 4 (Garay Declaration); Pet’r’s Ex. 64, at 4 (Calderon Declaration); Pet’r’s Ex. 65 at 6-7
(Carrillo Declaration).
Notwithstanding these symptoms, the record reflects that Ms. Chinea did not seek any
medical treatment during November and December other than with her gynecologist, Dr.
Adrienne Lara. On December 10, 2012, Ms. Chinea visited Dr. Lara for her annual exam. Pet’r’s
Ex. 4, at 3, Docket No. 7 (Dr. Lara’s Physical Examination Report). Dr. Lara’s notes of that visit
do not contain any mention of non-gynecological complaints such as weakness, fatigue, or
tingling of the limbs.
Id. at 4. To the contrary, her exam notes indicate that Ms. Chinea
“continues to be successful and it is going to be a good year” and that “|t]here was nothing else
on her mind.”
Id. Ms. Chinea had a follow-up appointment with Dr, Lara on December 21.
Id. at
1-2. Dr. Lara did not document any non-gynecological complaints during this visit either.
Id.
Ms. Chinea testified at the hearing that, despite the absence of any mention of non-
gynecological symptoms in Dr, Lara’s notes, she discussed her lack of energy and other
symptoms with Dr. Lara during the December 2012 appointments. Hr’g Tr. at 34; see also Pet’r’s
Decl. at 3 (stating that at the December appointments Ms. Chinea told Dr. Lara about her loss of
energy, as well as other symptoms, including hoarse voice and difficulty swallowing). Ms.
Chinea also submitted typewritten notes into the record that she alleged she had written before
her appointments with Dr. Lara. Pet’r’s Ex. 82 and 83, Docket No. 81 (Ms. Chinea’s notes); Hr’g
Tr. at 34-35. The notes, dated December 10, 2012, reflect that Ms. Chinea wished to secure
“ouidance and support” regarding a number of medical problems, including exhaustion, severe
arm pain, lack of appetite, and a feeling of “coldness.” See Pet’r’s Ex, 82-83.
In addition, Ms. Chinea submitted a November 2014 letter signed by Dr. Lara. See Pet’r’s
Ex. 4. In the letter, Dr. Lara stated that during the December 2012 appointments Ms. Chinea had
reported “significant loss of energy on a daily basis” as well as, among other things, hoarseness,
throat swelling and difficulty swallowing, numbness of the extremities and sensitivity to cold,
and weakness in her wrists and arms. Id, at 24. Dr. Lara also stated in her letter that Ms. Chinea
was “depressed and tearful” during the appointment. Id.’
In mid-January, Ms. Chinea began to experience watery eyes and respiratory symptoms
that she initially believed were caused by an allergic reaction to a cat. Id.; Pet’r’s Ex. 7, at 4-5,
Docket No. 8 (Community Memorial Health System History and Physical Report). On January
27, 2013, Ms. Chinea was unable to make remarks at a book-signing event because her voice
“was totally [gone]”—.c., it was “very raspy and very deep.” Hr’g Tr. at 51. By January 28, Ms.
Chinea began to experience “profound weakness” as well as other symptoms, including
headaches, dizziness, balance issues, congestion, and problems with her voice. Pet’r’s Ex. 7, at 4;
' Tn an August 2016 deposition, Dr. Lara attempted to explain the discrepancy between her
contemporaneous notes and the representations made in her November 2014 letter. She testified
that the reason she had not included the additional symptoms in her records of the December
2012 visits was because the exams were focused on gynecological issues. See Docket No. 58 at
9-10, 21-22 (Deposition of Dr. Adrienne Lara).
3
Pet’r’s. Ex. 1, at 40. On January 29, Ms. Chinea recalled “seeing double” when she ran into a
neighbor’s garage with her car. Pet’r’s Decl. at 3.
On January 30, 2013, Ms. Chinea’s husband called Dr. Neira for guidance in light of Ms.
Chinea’s worsening condition.
Id. He reported that his wife’s symptoms included a fever of
ninety-nine degrees, weakness, a headache, dizziness, two days of congestion that had worsened
the previous night, and an inability to get out of bed.
Id. In response, Dr. Neira’s office
prescribed Tamiflu. Pet’r’s Ex. 1, at 39.
TE. The GBS Diagnosis and Treatment
On January 31, 2013, Ms. Chinea went to the emergency room at Community Memorial
Health System. Special Master’s Decision (“SM Dec.”) at 3, 9, Docket No. 89; Pet’r’s Ex. 7, at
4, At that time, she could not walk, stand, or keep her head up, and she had difficulty
swallowing. Pet’r’s Ex. 7, at 4; Pet’r’s Decl. at 4. She complained of “generalized weakness” and
reported the upper respiratory symptoms that had begun in mid-January. Pet’r’s Ex. 7, at 4. A
physical examination showed slurred speech, slow movements in all four limbs, absent deep
tendon reflexes, decreased muscle strength, and paresthesia of the hands and feet.
Id. at 5.
Mr. Chinea provided information for the emergency room intake notes. See Hr’g Tr. at
56—58. The notes characterize Ms. Chinea as having been in her “normal state of health” until
approximately a week earlier.
Id. at 8, 10. At the hearing, Ms. Chinea rejected the
characterization of her health as having been “normal” until a week earlier.
Id. at 60-61, 63-64.
She stated that the notes were misleading or inaccurate except to the extent that they referred to
“how [she] used to be” (i.e., before November 2012).
Id. at 88; see also
id. at 138-39 (testimony
of Mr. Chinea to the same effect).
Ms. Chinea was intubated and placed on ventilator support after emergency room doctors
diagnosed acute respiratory failure with upper airway edema and diffuse neuromuscular
weakness.
Id. at 7-8. During a February 1, 2013 emergency room consultation, neurologist Dr.
Francisco Torres opined that Ms. Chinea “could have a clinical picture compatible with [GBS]
given [her] flu-like symptoms and then diffuse generalized weakness” in the days preceding her
visit to the emergency room.
Id. at 11.
Ms. Chinea subsequently tested positive for the GQ1B antibody, which is an
antiganglioside antibody associated with the Miller-Fisher variant of GBS.
Id. at 1-2, 52, 71-72;
see I, Nachamkin, et al., Anti-Ganglioside Antibody Induction by Swine (A/NJ/1976/HIN1) and
Other Influenza Vaccines: Insights into Vaccine-Associated Guillain-Barre Syndrome, 198 J.
Infect. Disease 226 (2008), filed as Pet’r’s Ex. 39, Docket No. 32 (“Nachamkin”). As a result,
she was treated with a five-day course of intravenous immunoglobulin (“TVIG”). Pet’r’s Ex. 7, at
2, 72.
On February 15, Ms. Chinea was extubated and monitored for treatment success.
Id. at 2.
She was discharged and transferred for acute inpatient rehabilitation on February 26 with a final
hospital diagnosis of GBS, Miller-Fisher variant. Id.; see also Pet’r’s Ex. 6, at 10, Docket No. 7
(Rehabilitation Discharge Summary).
The fact that Ms. Chinea had received a flu shot was noted by hospital personnel on the
day she was admitted. See Pet’r’s Ex. 7, at 4 (comments by Dr. Diane Li in medical history and
physical report dated January 31, 2013, noting that Ms. Chinea “did receive a flu shot this
season”). Ms. Chinea’s hospital records contain no indication, however, that any of her treating
physicians suspected that there was a connection between the vaccine and her GBS?
Over the next few months, Ms. Chinea received further treatment for her GBS. See, e.g.,
Pet’r’s Ex. 1, at 7-10; Pet’r’s Ex. 3, at 11-14, Docket No. 7 (Neurologist Medical Report). Ms.
Chinea’s GBS symptoms substantially subsided by the end of 2013, though she continued to
receive physical therapy through 2014. Pet’r’s Ex. 3, at 15-17; Pet’r’s Ex. 10, at 14. But see
Pet’r’s Ex. 9 (letter from Dr. Neira indicating that Ms. Chinea had not recovered completely as
of July 2014).
lll. The Vaccine Claim
On January 30, 2015, Ms. Chinea filed a petition for compensation under the Vaccine Act
in the Court of Federal Claims. Pet’r’s Pet. for Compensation, Docket No. 1. She alleged that the
flu vaccination she received on October 31, 2012 caused her GBS. Pet’r’s Decl. at 1. The case
was assigned to Chief Special Master Denise Vowell on January 30, 2015. Docket No. 5. On
February 17, 2015, both parties filed a Joint Statement of Completion, and thereafter filed
additional medical records. Docket Nos. 10, 14-17, 22-24, 29-30, 34. The HHS Secretary filed a
Rule 4(c) report asserting that Ms. Chinea was not entitled to compensation on December 1,
2015. Docket No. 41.
Ms. Chinea and the Secretary filed expert reports on August 21, 2015 and December I,
2015, respectively. Docket Nos. 31, 42. Pursuant to the Special Master’s request to supplement
the record with additional expert support, Ms. Chinea filed a second report prepared by her
expert, Dr. Lawrence Steinman, on February 16, 2017. Docket No. 64. The Secretary responded
with a supplemental report from his expert, Dr. Peter Donofrio, on April 24, 2017. Docket No.
65. On January 16, 2018, the case was reassigned to Special Master Brian Corcoran. Docket Nos.
68-69.
* The Court notes that during a June 2013 appointment with Dr. Neira, Ms. Chinea told him that
one of the hospital’s doctors had told her that her GBS was an adverse reaction to the flu
vaccine. Pet’r’s Ex. 1, at 7. Then, in a report prepared during a follow-up visit in October 2013,
Dr. Neira noted that the GBS “may have been caused by [the] flu vaccine” and advised that Ms.
Chinea not receive any flu vaccinations in the future.
Id. at 73, 77. Dr. Neira’s final VAERS
report similarly stated that Ms. Chinea had experienced fatigue and other symptoms before
Thanksgiving 2012, and posited that the onset of GBS was connected to the October 2012 flu
vaccine. Pet’r’s Ex. 10, at 17, Docket No. 14 (VAERS Email Correspondence); see Pet’r’s Ex. 9,
at 1-5, Docket No. 8 (VAERS Supplemental Report). The onset date for Ms. Chinea’s GBS
symptoms, however, was reported as January 31, 2013. Pet’r’s Ex. 2, at 2.
IV. The Expert Testimony
A hearing was held on Ms. Chinea’s claim on August 6 and 7, 2018. See Docket No. 82.
In addition to the testimony of Ms. Chinea and four other lay witnesses, each party presented
expert testimony regarding the critical issue of whether Ms. Chinea’s GBS was caused by the flu
vaccination she received on October 31, 2012.
Dr. Lawrence Steinman testified as Ms. Chinea’s expert.? According to Dr. Steinman,
Ms. Chinea exhibited symptoms of GBS as early as Thanksgiving 2012 when she experienced
double vision, fatigue, taste disturbance, voice hoarseness, feelings of tingling/cold, and
swallowing difficulties. Hr’g Tr. 23440. He attributed these symptoms to inflammation of
various nerves typically affected by GBS.
Id. at 236, 240-41, 277-78. Dr. Steinman conceded
that the relatively long gap between the vaccination and Ms. Chinea’s hospitalization was
“atypical,” but proposed that her GBS “smoldered” for weeks before it became acute, resulting in
Ms. Chinea’s visit to the emergency room.
Id. at 251-52. Alternatively, he testified, he could
support the theory of an eleven- or twelve-week onset for GBS resulting from a flu vaccination.
Id. at 256-57.
Dr. Peter Donofrio testified on behalf of the Secretary.* Dr. Donofrio testified that GBS
symptoms typically progress “fairly rapidly,” and that common symptoms are
numbness/tingling, weakness in upper and lower extremities, lower back pain, absent reflexes,
and unsteady gait.
Id. at 304-05, 311-12. In his view, generalized fatigue is a symptom that may
result after a “full-blown” bout of GBS; it is not a pre-acute presenting symptom of GBS.
Id. at
312. He thus disputed Dr. Steinman’s assertion that Ms. Chinea’s GBS “lurked” for months
before reaching its nadir.
Id. at 316, 353-55, Instead, Dr. Donofrio concluded, the likely onset of
Ms. Chinea’s GBS occurred closer to her January 2013 hospitalization, thus falling beyond the
six- to eight-week period that he testified was the medically appropriate timeframe for the
occurrence of vaccine-induced GBS.
Id. at 322-23, 334; Resp’t’s Ex. A, at 8, Docket No. 42
(“Donofrio Report”); Resp’t’s Ex. F, at 3, Docket No. 65 (“Donofrio Supplemental Report”).
3 Dr. Steinman obtained his medical degree from Harvard Medical School, where he completed a
fellowship in chemical neurobiology. Hr’g Tr. at 214; see also CV, filed as Ex. 76 (Docket No.
74-1) (“Steinman CV”) at 1. After medical school, Dr. Steinman went on to complete pediatrics
and neurology residencies at Stanford University. Hr’g Tr. at 214; Steinman CV at |. He then
joined the faculty at Stanford in 1980, where he presently serves as the George A. Zimmerman
Professor of Neurological Sciences, Neurology, Genetics, and Pediatrics. Hr’g Tr. at 216;
Steinman CV at 1.
4 Dr. Donofrio is a professor of neurology and director of the MDA and ALS clinics at the
Vanderbilt University Medical Center. Hr’g Tr. at 301. He received his B.S. at the University of
Notre Dame, and then attended the Ohio State University School of Medicine for his M.D.
Id. He
is board certified in neurology, internal medicine, electrodiagnostic medicine, and neuromuscular
disorders. CV, filed as Ex. B (Docket No. 42-2} (“Donofrio CV”) at 3.
6
V. The Special Master’s Decision
On March 15, 2019, the Special Master issued an opinion ruling that Ms. Chinea was not
entitled to compensation under the Vaccine Act. SM Dec. at 45, Docket No. 89. In reaching his
conclusion, the Special Master applied the three-prong test for establishing causation set forth by
the Federal Circuit in Althen v. Secretary of Health & Human Services.,
418 F.3d 1274, 1278
(Fed. Cir. 2005). Noting the “well-established” connection between the flu vaccine and GBS, the
Special Master found preponderant evidence of a medical theory causally connecting the flu
vaccine to GBS, thus satisfying prong one of Althen. SM Dec. at 40. The Special Master
determined, however, that Ms. Chinea had not satisfied prong three of Althen because the onset
date of her GBS (mid-to-late January 2013) was too long after the administration of her October
2012 flu vaccination. See
id. at 41.
The Special Master noted that it was undisputed that Ms. Chinea did not see a medical
professional about her alleged GRS symptoms between the time she received her vaccination on
October 31, 2012 and late January 2013.
Id. He further observed that contemporaneous medical
records did not corroborate that Ms. Chinea had complained to any doctor about those symptoms
until late January.
Id. In that regard, he found that Dr. Lara’s November 2014 letter purporting to
document symptoms not recorded in her December 2012 report lacked credibility.
Id. at 41-42.
The Special Master found “more persuasive,” however, the testimony of Ms. Chinea’s
witnesses (whom he characterized as honest and credible).
Id. at 42. Based on that testimony he
concluded that Ms. Chinea did in fact suffer from “overall fatigue/malaise” beginning in
November 2012 through January 2013, and that the symptoms about which she complained
“affected her professional and social life.”
Id.
Nonetheless, the Special Master concluded that “in light of what is known regarding []
typical GBS,” Ms. Chinea did not establish that any of the symptoms she suffered in November
and December of 2012 “represented the onset of her subsequently-diagnosed GBS.”
Id. Dr.
Donofrio’s testimony, he explained, “persuasively established that GBS is understood to be an
acute-onset monophasic disease.” Id, Therefore, although some of Ms. Chinea’s reported
symptoms, such as malaise and fatigue, “could be secondarily associated with GBS,” they were
not “presenting symptoms of the illness.”
Id. (emphasis added).
Further, the Special Master rejected as unsupported by the medical literature Dr.
Steinman’s theory, which he characterized as positing the existence of “‘a smoldering form of
GBS that could not only begin with secondary symptoms but thereafter progressively meander,
only becoming acute over an eleven-week period, and long after the antibodies he deemed
essential to the condition would have first been produced in reaction to the flu vaccine.” Id, at 43.
The Special Master opined that “despite his immense credentials as an immunologist,” Dr.
Steinman “does not have a current, demonstrated expertise in studying or treating GBS sufficient
to breathe life into this theory.” Id,
The Special Master also found Dr. Steinman’s overall credibility “greatly undercut” by
certain comments he had made at the hearing, which the Special Master characterized as
“stepp[ing] out of his role as medical/scientific expert and into the shoes of judicial ‘color
commentator,’ expressing views about the proper apportionment of legal burdens and standards
7
applicable in the Vaccine Program, or making asides about his responsibilities as an expert based
upon his understanding of the applicable legal standards.”
Id. at 26-27, 43. In particular, the
Special Master cited Dr. Steinman’s statements that he could “probably structure a theory”
identifying the vaccine as a substantial cause of Ms. Chinea’s GBS even if another cause was
identified, and suggesting that the method by which he would diagnose the cause of GBS “in the
real world” is different from how he would do so in a Vaccine Program case, where he is tasked
by petitioners to propose a vaccine cause.
Id. at 26 (citing Hr’g Tr. at 217, 234, 265-66, 285,
287-88).
For these reasons, the Special Master concluded that the record did not support the
conclusion that Ms. Chinea’s fall 2012 symptoms were GBS-related. He therefore found that the
onset of her GBS occurred no earlier than January 20-28, 2013. Id, at 43. Given that finding, the
Special Master concluded that Ms. Chinea had failed to show a proximate temporal relationship
between the vaccine and GBS as required under Althen prong three. See
id. at 45. He noted that
the “most reliable medical literature offered in this case” sets a reasonable timeframe for GBS
onset post-vaccine administration at no more than six to eight weeks (which is also the
timeframe set for the Table version of the claim).
Id. at 44. He determined that Ms. Chinea’s
arguments in support of a longer timeframe “Jack[ed] reliable support in science or fact.”
Id.
In short, the Special Master concluded that “the evidentiary record does not support
Petitioner’s contention that the flu vaccine she received in October 2012 caused her GBS in the
timeframe proffered, or that the symptoms she experienced in November and December 2012
were manifestations of that GBS.” Id, at 45. He therefore dismissed Ms. Chinea’s claim.
Id. °
VI. The Motion for Review
On April 12, 2019, Ms. Chinea, proceeding pro se, filed the present motion for review.
See generally Pet’r’s Mot. For Review (“Pet’r’s Mot.”), Docket No. 94. Ms. Chinea’s central
argument is that the Special Master erred in crediting the opinion of Dr. Donofrio over that of
Dr. Steinman regarding the onset date of her GBS.
The government timely filed its response to Ms. Chinea’s motion on May 15, 2019.
Docket No. 105. The motion is now fully briefed and ripe for review.
DISCUSSION
I. Jurisdiction
Congress established the National Vaccine Injury Compensation Program in 1986 to
provide a no-fault compensation system for vaccine-related injuries and deaths. Figueroa v.
Sec’y of Health & Human Servs.,
715 F.3d 1314, 1316-17 (Fed. Cir..2013). A petition seeking
> Because he determined that “the timeframe for onset of [Ms. Chinea’s] GBS was too remote to
be medically reasonable,” the Special Master found it unnecessary to undertake a detailed Althen
prong two analysis. SM Dec. at 44 n.43. He noted, however, that in his view the record did not
support a conclusion that the flu vaccine caused Ms. Chinea’s GBS because “[h]er symptoms . . .
likely caused her January illness.”
Id.
compensation under the Vaccine Act is filed in the Court of Federal Claims, after which the
Clerk of Court forwards it to the Chief Special Master for assignment to a special master. 42
U.S.C. § 300aa-11(a)(1). The special master to whom the petition is assigned “issue[s] a decision
on such petition with respect to whether compensation is to be provided under the [Vaccine Act]
Program and the amount of such compensation.”
Id. § 300aa-12(d)(3)(A). That decision is
subject to review in the Court of Federal Claims in accordance with 42 U.S.C. § 300aa-12(e)(1).
This Court, therefore, has jurisdiction over Ms. Chinea’s motion for review of the Special
Master’s adverse decision regarding her entitlement to compensation under the Vaccine Act.
IL. Standard of Review
On review of a special master’s decision in a vaccine case, the Court applies the
“arbitrary and capricious” standard to factual findings and the “not in accordance with law”
standard to legal rulings. Moberly v. Sec’y of Health & Human Servs., 592 F.3d 1315,1321 (Fed.
Cir. 2010). “The arbitrary and capricious standard of review is difficult for an appellant to satisfy
with respect to any issue, but particularly with respect to an issue that turns on the weighing of
evidence by the trier of fact.” Lampe v. Sec’y of Health & Human Servs.,
219 F.3d 1357, 1360
(Fed. Cir. 2000). The Court “dofes] not reweigh the factual evidence, assess whether the special
master correctly evaluated the evidence, or examine the probative value of the evidence or the
credibility of the witnesses,” because those “are all matters within the purview of the fact
finder.” Porter v. Sec’y of Health & Human Servs.,
663 F.3d 1242, 1249 (Fed. Cir. 2011) (citing
Broekelschen v. Sec’y of Health & Human Servs.,
618 F.3d 1339, 1349 (Fed. Cir. 2010)).
In short, “as long as a special master’s finding of fact is ‘based on evidence in the record
that [is] not wholly implausible,’” the Court must uphold it.
Id. (quoting Cedillo v. Sec’y of
Health & Human Servs.,
617 F.3d 1328, 1338 (Fed. Cir. 2010) (alteration in original)). This
standard of review is “uniquely deferential” to special masters’ decisions. Milik v. Sec’y of
Health & Human Servs.,
822 F.3d 1367, 1376 (Fed. Cir. 2016) (quoting Hodges v, Sec’y of
Health & Human Servs.,
9 F.3d 958, 961 (Fed. Cir. 1993)). “If the special master ‘has considered
the relevant evidence of record, drawn plausible inferences and articulated a rational basis for the
decision,’ then reversible error is ‘extremely difficult to demonstrate.’”
Id. (quoting Hines v.
Sec’y of Health & Human Servs.,
940 F.2d 1518, 1528 (Fed. Cir. 1991)).
IU. Merits
A petitioner must prove by a preponderance of the evidence that a vaccine caused the
injury at issue to secure compensation under the Vaccine Act for a non-Table injury. See 42
U.S.C. §§ 300aa-11(c)(1), -13(a)(1)(A); see also
Broekelschen, 618 F.3d at 1342 (citing
Moberly, 592 F.3d at 1321). Specifically, a petitioner must establish that the vaccine was both
the “but-for” cause of the injury and a substantial factor in bringing the injury about.
Moberly,
592 F.3d at 1321.
To prove causation, a petitioner must satisfy all three of the elements set forth by the
Federal Circuit in Althen. Those elements are “(1) a medical theory causally connecting the
vaccination and the injury; (2) a logical sequence of cause and effect showing that the
vaccination was the reason for the injury; and (3) a showing of proximate temporal relationship
between vaccination and injury.”
Althen, 418 F.3d at 1278. “Once the petitioner has
demonstrated causation, she is entitled to compensation unless the government can show by a
preponderance of the evidence that the injury is due to factors unrelated to the vaccine.”
Broekelschen, 618 F.3d at 1342 (citing Doe v. Sec’y of Health & Human Servs.,
601 F.3d 1349,
1351 (Fed. Cir. 2010); 42 U.S.C. § 300aa-13(a)(1)(B)).
The Special Master’s dismissal of Ms. Chinea’s petition was based on his conclusion that
she failed to satisfy Althen prong three, which, as noted, required her to prove a proximate
temporal relationship between the vaccine and her GBS. SM Dec. 44-45. He held that a
reasonable timeframe for the onset of GBS after a vaccination is six to eight weeks. Id, at 44. He
further found that the onset of Ms. Chinea’s GBS occurred outside that time period, in the last
week or so of January 2013 (eleven or twelve weeks after the vaccination).
Id. at 43.
In her motion for review, Ms. Chinea does not appear to challenge the Special Master’s
determination that six to eight weeks is a reasonable timeframe for the onset of GBS caused by a
flu vaccine. Instead, she asks the Court to set aside the Special Master’s factual determination
that the onset date for her GBS occurred a week or two before she went to the emergency room
on January 31, 2013, rather than in November 2012, a few weeks after she received the vaccine.
Pet’r’s Mot. at 2. She relies upon Dr. Steinman’s theory that---although the symptoms of her
GBS did not become acute until the end of January 2013—-she had symptoms of GBS as early as
November 2012 and those symptoms “smoldered” until they became acute in late January 2013.
Id. at 1-2. She contends that the Special Master erred in failing to credit Dr. Steinman’s opinion
regarding the “atypical” nature of her illness and instead relying upon what she characterizes as
the “orthodox” views of Dr. Donofrio.
Id. at 2.
In light of this Court’s extremely narrow scope of review with respect to special masters’
factual findings, Ms. Chinea’s arguments do not provide a sufficient basis for reversing the
Special Master’s decision. Where—-as here—each side offers conflicting expert testimony, the
Special Master is empowered to make a decision “based on the credibility of the experts and the
relative persuasiveness of their competing theories.”
Broekelshen, 618 F.3d at 1347. That is
precisely what the Special Master did in this case.
It bears noting that—-notwithstanding the absence of contemporaneous medical records—
the Special Master credited the testtmony of Ms. Chinea-and her witnesses that she experienced
“overall fatigue/malaise, inter alia, beginning in November 2012 and running into January 2013,
and that these symptoms affected her professional and social life.” SM Dec. at 42. Nonetheless,
the Special Master ruled that Ms. Chinea was not entitled to compensation under the Vaccine Act
because he found that the record was “not supportive of the conclusion that Petitioner was
experiencing nascent GBS in November or December 2012 .. . or that any of these earlier
symptoms had anything at all to do with Petitioner’s late-January 2013 symptoms.”
Id. at 42-43.
in so holding, the Special Master found Dr. Donofrio’s opinion more persuasive than that
of Dr. Steinman. SM Dec. at 42. He also found Dr. Steinman’s credibility undermined by certain
statements he made at the hearing, in which (as described above) he offered commentary on the
legal standards that govern proof of causation under the Vaccine Act.
Id. at 43. Indeed, the
Special Master noted that he had criticized Dr. Steinman in previous cases “for testifying in this
manner,” which he characterized as “wholly unhelpful and irrelevant.”
Id. at 43 n.42.
10
Thus, Dr. Donofrio characterized GBS as “an acute-onset, monophasic disease.”
Id. at 42.
He testified that GBS typically evolves “fairly rapidly” (i.e., over several days) and that common
presenting symptoms are numbness/tingling, weakness in upper and lower extremities, lower
back pain, absent reflexes, and unsteady gait. Hr’g Tr. at 304-05, 311-12, He noted that “ninety
percent of GBS patients reach the nadir of their illness between two and four weeks following
onset, with a plateauing of symptoms thereafter.” SM Dec. at 27 (citing Hr’g Tr. at 304).
The course of Ms. Chinea’s symptoms from November through January did not fit the
pattern Dr. Donofrio described. The Special Master found persuasive Dr. Donofrio’s testimony
that the kind of generalized fatigue Ms. Chinea experienced starting in November 2012 is not a
pre-acute presenting symptom of GBS, but rather is a symptom that can follow a “full-blown”
course.
Id. (citing Hr’g Tr. at 312). Relying on Dr. Donofrio’s testimony, the Special Master
placed the onset of Ms. Chinea’s GBS in mid-to-late January 2013, one or two weeks before she
went to the emergency room. Id, at 43.
The Special Master found Dr. Steinman’s testimony, on the other hand, unpersuasive. Dr.
Steinman agreed that the literature showed that a typical course of GBS includes paresthesia,
pain, generalized weakness, sensory disturbances, unsteady gait, and loss of bowel function. See,
e.g., J. Menze, et al., Textbook of Peripheral Neuropathy, 167 (1st ed. 2012), filed as Pet’r’s Ex.
80, Docket No. 74 (“Menze”). Dr. Steinman explained that the Miller-Fisher variant of GBS also
results in eye movement abnormalities and ataxia. Hr’g Tr. at 218, 239. He posited that while the
course of Ms. Chinea’s symptoms during November and December was “atypical,” it reflected
that she experienced what he called a “smoldering” form of GBS. Id, at 232, 240-41, 299, 357,
359,
The Special Master rejected Dr. Steinman’s theory for several reasons. First, he noted
that the theory was not recognized in the medical literature before him, including the literature
upon which Dr. Steinman relied. SM Dec. at 43. For example, the Special Master found
unavailing Dr, Steinman’s reliance upon J. Wanschitz, et al., Distinct Time Pattern of
Complement Activation and Cytotoxic T Cell Response in Guillain-Barre Syndrome, 126 Brain
2034 (2003) (“Wanschitz”). See Pet’r’s Ex. 69, Docket No. 64. He observed that “literature like
Wanschitz discussed purportedly longer timeframes for GBS only after a presentation
sufficiently acute for a diagnosis, and was thus unhelpful in establishing GBS’s course measured
from the time of the proposed insult (in this case, vaccination).” SM Dec. at 43. The Special
Master similarly found unpersuasive a GBS textbook excerpt that Dr. Steinman cited which
stated that once GBS is diagnosed, it could “progress for more than four weeks until it really
bottoms out.”
Id. at 25 (quoting Hr’g Tr. at 252). This text, the Special Master observed, “applies
only to the course of GBS following its onset (which in this case would mean that Petitioner’s
nadir should have been reached by the end of December at the latest—a month before Petitioner
sought emergency treatment).”
Id.
Further, the Special Master explained that Dr. Steinman had no “current, demonstrated
expertise in studying or treating GBS sufficient to breathe life into his theory.”
Id. at 43. He
concluded that Dr. Steinman’s theory that Ms. Chinea’s GBS first manifested itself in November
2012 and subsequently “smoldered” beneath the surface was not grounded in medical evidence,
but was “the product of his admitted goal: to ‘provide’ a theory that would be useful to the
Petitioner.”
Id. (emphasis added). And the Special Master determined that Dr. Steinman’s
il
statements to that effect, as well as Dr. Steinman’s legal asides regarding the Vaccine Act, were
“wholly inappropriate ... at [a] hearing” and “greatly undercut [his] overall credibility.”
Id.
It is the province of the special master to make credibility determinations regarding the
testimony of the witnesses before him, including expert witnesses like Dr. Donofrio and Dr.
Steinman. The Court, accordingly, concludes that the Special Master’s decision to give greater
weight to Dr. Donofrio’s opinion than Dr. Steinman’s was not arbitrary or capricious but was
instead a reasonable exercise of his discretion as the trier of fact.
Ms. Chinea’s remaining criticisms of the Special Master’s decision also lack merit. She
observes that Dr. Donofrio suggested that her GBS may have been caused by a pre-onset upper
respiratory infection (“URI”), a theory she contends lacks any support in the evidence. Pet’r’s
Mot. at 1. But as the Special Master noted, Dr. Donofrio relied upon concerns expressed by at
least two other physicians that Ms. Chinea may have suffered from a URI in the two weeks
immediately before she went to the emergency room. SM Dec. at 31 (citing Pet’r’s Ex. 7, at 4—
5). He also noted that there was other radiological evidence suggestive of a URI.
Id. Such an
infection provided a possible alternative cause for Ms. Chinea’s GBS according to Dr. Donofrio,
who asserted that “i]t is well known that [GBS] is often preceded by an upper or lower...
respiratory tract infection or gastroenteritis in approximately 60-70% of patients.”
Id. (quoting
Donofrio Report at 8).
In any event, the Special Master did not base his decision in any respect on the possibility
that Ms. Chinea’s GBS was caused by a URI. Instead, his decision was based on his conclusion
that Ms. Chinea had failed to establish that it was caused by the flu vaccine. Further, “the
absence of alternative causes for a condition does not alone suffice to ascribe causation to the
vaccine.” See, e.g.,
Lampe, 219 F.3d at 1361 (citing Grant v. Sec’y of Health & Human Servs.,
956 F.2d 1144, 1149 (Fed. Cir. 1992)). Ms. Chinea’s challenge to Dr. Donofrio’s theory of an
alternative cause for her GBS therefore does not supply a basis for reversing the Special Master’s
determination.
In short, the Special Master based his decision on all of the evidence before him and on
his assessment of the credibility of the witnesses. He provided an adequate and reasonable
explanation for his finding that the October 2012 flu vaccine did not cause Ms. Chinea’s GBS.
The inferences he drew and the conclusions he reached were well explained and grounded in the
record. The Court, accordingly, must sustain his decision.
CONCLUSION
On the basis of the foregoing, Ms. Chinea’s motion for review is DENIED and the
Special Master’s ruling is SUSTAINED. The Clerk is directed to enter judgment accordingly.
Each side shall bear its own costs.
IT IS SO ORDERED. LL Li fi
ELAINE D. KAPLAN
Judge
12